ITRM RSI Chart
Last 7 days
-9.7%
Last 30 days
-4.1%
Last 90 days
-5.4%
Trailing 12 Months
27.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2019 | 715.0K | 530.0K | 276.0K | 37.0K |
2018 | 598.3K | 688.5K | 778.8K | 869.0K |
2017 | 0 | 0 | 0 | 508.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 22, 2023 | dunne michael w. | bought | 35,000 | 1.4 | 25,000 | - |
Dec 18, 2023 | dunne michael w. | bought | 18,442 | 1.8442 | 10,000 | - |
Dec 01, 2023 | puttagunta sailaja | sold (taxes) | -6,217 | 2.12 | -2,933 | chief medical officer |
Dec 01, 2023 | puttagunta sailaja | acquired | - | - | 8,333 | chief medical officer |
Nov 22, 2023 | dunne michael w. | bought | 40,690 | 2.0345 | 20,000 | - |
Nov 20, 2023 | fishman corey n. | bought | 15,863 | 1.5863 | 10,000 | chief executive officer |
Oct 01, 2023 | dunne michael w. | acquired | - | - | 3,487 | - |
Oct 01, 2023 | hunt ronald | acquired | - | - | 5,479 | - |
Jul 01, 2023 | dunne michael w. | acquired | - | - | 1,779 | - |
Jul 01, 2023 | hunt ronald | acquired | - | - | 2,796 | - |
Which funds bought or sold ITRM recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Ancora Advisors LLC | unchanged | - | -16.00 | 59.00 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | -2,356 | 8,438 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 721 | 721 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | new | - | 43,186 | 43,186 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -99.00 | -20,000 | - | -% |
May 15, 2024 | Point72 Asset Management, L.P. | new | - | 668,360 | 668,360 | -% |
May 14, 2024 | NewEdge Advisors, LLC | sold off | -100 | -197 | - | -% |
May 14, 2024 | New Leaf Venture Partners, L.L.C. | unchanged | - | -41,746 | 149,509 | 0.13% |
May 13, 2024 | NATIONAL BANK OF CANADA /FI/ | unchanged | - | -1.00 | 3.00 | -% |
May 13, 2024 | UBS Group AG | added | 142 | 8,759 | 18,509 | -% |
Unveiling Iterum Therapeutics plc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Iterum Therapeutics plc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Iterum Therapeutics plc News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
Revenue | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | -25.2% | 23.00 | 31.00 | 27.00 | 21.00 | 24.00 | 25.00 | 16.00 | - | - | - |
S&GA Expenses | -21.7% | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | - | - |
R&D Expenses | -25.6% | 21.00 | 28.00 | 24.00 | 17.00 | 21.00 | 23.00 | 14.00 | - | - | - |
Interest Expenses | -7.0% | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
Income Taxes | -52.9% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
Earnings Before Taxes | 24.3% | -23.59 | -31.17 | -27.48 | -20.45 | -24.05 | -24.80 | -15.68 | - | - | - |
Net Income | 24.4% | -23.64 | -31.27 | -27.64 | -20.58 | -24.26 | -24.90 | -15.75 | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -25.3% | 20.00 | 26.00 | 40.00 | 51.00 | 58.00 | 67.00 | 72.00 | 77.00 | 84.00 | 92.00 | 98.00 | 106 | 115 | 33.00 | 26.00 | 32.00 | 42.00 | 26.00 | 51.00 | 71.00 | 89.00 |
Current Assets | -25.6% | 19.00 | 26.00 | 39.00 | 48.00 | 54.00 | 62.00 | 67.00 | 71.00 | 76.00 | 83.00 | 90.00 | 96.00 | 104 | 21.00 | 12.00 | 18.00 | 29.00 | 12.00 | 37.00 | 59.00 | 77.00 |
Cash Equivalents | 21.7% | 7.00 | 6.00 | 5.00 | 14.00 | 17.00 | 21.00 | 20.00 | 9.00 | 31.00 | 27.00 | 36.00 | 37.00 | 67.00 | 15.00 | 9.00 | 12.00 | 23.00 | 5.00 | 29.00 | 51.00 | 65.00 |
Net PPE | -13.7% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -21.1% | 26.00 | 33.00 | 36.00 | 44.00 | 39.00 | 39.00 | 39.00 | 33.00 | 35.00 | 41.00 | 46.00 | 59.00 | 84.00 | 83.00 | 82.00 | 80.00 | 84.00 | 52.00 | 54.00 | 47.00 | 38.00 |
Current Liabilities | 31.6% | 18.00 | 14.00 | 16.00 | 11.00 | 8.00 | 9.00 | 8.00 | 7.00 | 10.00 | 13.00 | 18.00 | 34.00 | 44.00 | 42.00 | 41.00 | 41.00 | 47.00 | 37.00 | 37.00 | 28.00 | 18.00 |
Long Term Debt | -2.0% | 11.00 | 11.00 | 12.00 | 12.00 | 11.00 | 10.00 | 9.00 | 9.00 | 8.00 | 7.00 | 6.00 | 5.00 | 6.00 | 22.00 | 22.00 | 21.00 | 19.00 | 8.00 | 9.00 | 11.00 | 12.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | 2.00 | 3.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 3.00 | 2.00 |
LT Debt, Non Current | -100.0% | - | 11.00 | 12.00 | 12.00 | 11.00 | 10.00 | 9.00 | 9.00 | 8.00 | 7.00 | 6.00 | 5.00 | 6.00 | 22.00 | 22.00 | 21.00 | 19.00 | 8.00 | 9.00 | 11.00 | 12.00 |
Shareholder's Equity | 4.0% | -6.15 | -6.40 | 3.00 | 7.00 | 19.00 | 28.00 | 33.00 | 44.00 | 49.00 | 50.00 | 52.00 | 47.00 | 32.00 | 51.00 | - | - | - | - | - | 25.00 | 52.00 |
Retained Earnings | -1.5% | -468 | -461 | -448 | -445 | -432 | -422 | -417 | -388 | -381 | -378 | -374 | -378 | -385 | -286 | -275 | -263 | -251 | -234 | -211 | -180 | -152 |
Additional Paid-In Capital | 1.6% | 462 | 455 | 452 | 452 | 452 | 451 | 450 | 431 | 429 | 429 | 425 | 423 | 416 | 236 | 220 | 215 | 209 | 209 | 208 | 204 | 204 |
Shares Outstanding | 19.1% | 15.00 | 13.00 | 13.00 | 13.00 | 13.00 | 12.00 | 12.00 | 12.00 | 12.00 | 11.00 | 10.00 | 12.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 14.00 | - | - | - | 37.00 | - | - | - | 411 | - | - | - | 14.00 | - | - | - | 37.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -1.9% | -13,083 | -12,843 | -9,265 | -7,632 | -9,590 | -4,265 | -4,539 | -6,264 | -3,405 | -2,459 | -3,910 | -8,341 | -1,132 | -9,031 | -4,417 | -13,689 | -27,391 | -23,053 | -25,410 | -18,406 | -15,053 |
Share Based Compensation | -0.7% | 138 | 139 | 142 | 110 | 393 | 457 | 422 | 1,984 | 1,895 | 1,967 | 1,512 | 559 | 281 | 126 | 850 | 1,186 | 597 | 499 | 561 | 573 | 540 |
Cashflow From Investing | -46.7% | 7,211 | 13,523 | 360 | 4,347 | 5,106 | 4,378 | 3,311 | -3,325 | 9,593 | -4,466 | 4,935 | -21,144 | -33,920 | - | -9.00 | - | - | -2.00 | 25.00 | 4,988 | 35,090 |
Cashflow From Financing | 1125.3% | 7,217 | 589 | 10.00 | 200 | 235 | 433 | - | - | -2,251 | -1,629 | -1,634 | -592 | 86,982 | 15,127 | 767 | 2,710 | 45,871 | -1,034 | 3,038 | 10.00 | 49.00 |
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ (3,977) | $ (6,432) |
General and administrative | (2,186) | (2,098) |
Total operating expenses | (6,163) | (8,530) |
Operating loss | (6,163) | (8,530) |
Interest expense, net | (487) | (399) |
Adjustments to fair value of derivatives | (386) | (878) |
Other (expense) / income, net | (17) | 41 |
Total other expense | (890) | (1,236) |
Loss before income taxes | (7,053) | (9,766) |
Income tax expense | (48) | (123) |
Net loss | $ (7,101) | $ (9,889) |
Net loss per share - basic | $ (0.46) | $ (0.78) |
Net loss per share - diluted | $ (0.46) | $ (0.78) |
Weighted average ordinary shares outstanding - basic | 15,432,693 | 12,681,900 |
Weighted average ordinary shares outstanding - diluted | 15,432,693 | 12,681,900 |
Statements of Comprehensive Loss | ||
Net loss | $ (7,101) | $ (9,889) |
Unrealized (loss) / gain on marketable securities | (1) | 219 |
Comprehensive loss | $ (7,102) | $ (9,670) |
Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 7,389 | $ 6,071 |
Short-term investments | 10,825 | 17,859 |
Income taxes receivable | 38 | |
Prepaid expenses and other current assets | 840 | 1,628 |
Total current assets | 19,054 | 25,596 |
Property and equipment, net | 44 | 51 |
Restricted cash | 34 | 34 |
Other assets | 493 | 578 |
Total assets | 19,625 | 26,259 |
Current liabilities: | ||
Accounts payable | 2,966 | 4,996 |
Accrued expenses | 1,859 | 7,761 |
Exchangeable Notes | 12,203 | |
Other current liabilities | 755 | 761 |
Income taxes payable | 11 | |
Total current liabilities | 17,794 | 13,518 |
Exchangeable Notes | 11,453 | |
Royalty-linked notes | 7,889 | 7,503 |
Other liabilities | 92 | 188 |
Total liabilities | 25,775 | 32,662 |
Commitments and contingencies (Note 14) | ||
Shareholders' deficit | ||
Undesignated preferred shares, $0.01 par value per share: 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued at March 31, 2024 and December 31, 2023 | ||
Ordinary shares, $0.01 par value per share: 80,000,000 shares authorized at March 31, 2024 and December 31, 2023, 16,470,414 shares issued at March 31, 2024; 13,499,003 shares issued at December 31, 2023 | 165 | 135 |
Additional paid-in capital | 462,084 | 454,759 |
Accumulated deficit | (468,399) | (461,298) |
Accumulated other comprehensive income | 1 | |
Total shareholders' deficit | (6,150) | (6,403) |
Total liabilities and shareholders' deficit | $ 19,625 | $ 26,259 |